Abstract

There are no pharmacological disease-modifying treatments that have an enduring effect to mitigate the seizures and comorbidities associated with established chronic temporal lobe epilepsy (TLE). Sodium selenate has been reported to have anti-epileptogenic effects if given before TLE onset. However, the majority of TLE patients already have established epilepsy when they present to the clinic. This study aimed to evaluate for disease modifying effects of sodium selenate treatment in the chronically epileptic rat post-status epilepticus (SE) model of drug-resistant TLE. Wistar rats underwent kainic acid-induced SE or sham. Ten-weeks post-SE, rats were randomly assigned to receive either sodium selenate, levetiracetam, or vehicle subcutaneous infusions continuously for 4 weeks. To evaluate the effects of the treatments, one week of continuous video-EEG was acquired before, during, and 4, 8 weeks post-treatment, followed by behavioral tests. Targeted and untargeted proteomics and metabolomics were performed on post-mortem brain tissue to identify potential pathways associated with modified disease outcomes. Telomere length has emerged as a potential biomarker of chronic brain conditions, was investigated as a novel surrogate marker of epilepsy disease severity in our current study. The results showed that sodium selenate treatment was associated with mitigation of measures of disease severity at 8 weeks post-treatment cessation; reducing the number of spontaneous seizures (p< 0.05), cognitive dysfunction (p< 0.05 in both novel object placement and recognition tasks), and sensorimotor deficits (p< 0.01). Moreover, in the brain post-mortem selenate treatment was associated with increased protein phosphatase 2A (PP2A) expression, reduced hyperphosphorylated tau, and reversed telomere length shortening (p< 0.05). Network medicine integration of multi-omics/ pre-clinical outcomes identified protein-metabolite modules positively correlated with the TLE phenotype. Our results provide evidence that treatment with sodium selenate results in a sustained disease-modifying effect in chronically epileptic rats in the post-KA SE model of TLE, including improved comorbid learning and memory deficits.

Data availability

All the metrodology and results form this work have been included in the manuscrit or as part of the supplementary material.Data has been deposited in Dryad https://doi.org/10.5061/dryad.37pvmcvnd

The following data sets were generated
    1. Casillas-Espinosa PM
    (2022) EEG and multi-omics data
    Dryad Digital Repository, doi:10.5061/dryad.37pvmcvnd.

Article and author information

Author details

  1. Pablo Miguel Casillas-Espinosa

    Department of Neuroscience, Monash University, Melbourne, Australia
    For correspondence
    pablo.casillas-espinosa@monash.edu
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-6199-9415
  2. Alison Anderson

    Department of Neuroscience, Monash University, Melbourne, Australia
    Competing interests
    The authors declare that no competing interests exist.
  3. Anna Harutyunyan

    Department of Neuroscience, Monash University, Melbourne, Australia
    Competing interests
    The authors declare that no competing interests exist.
  4. Crystal Li

    Department of Neuroscience, Monash University, Melbourne, Australia
    Competing interests
    The authors declare that no competing interests exist.
  5. Jiyoon Lee

    Department of Medicine, University of Melbourne, Parkville, Australia
    Competing interests
    The authors declare that no competing interests exist.
  6. Emma L Braine

    Department of Neuroscience, Monash University, Melbourne, Australia
    Competing interests
    The authors declare that no competing interests exist.
  7. Rhys D Brady

    Department of Neuroscience, Monash University, Melbourne, Australia
    Competing interests
    The authors declare that no competing interests exist.
  8. Mujun Sun

    Department of Neuroscience, Monash University, Melbourne, Australia
    Competing interests
    The authors declare that no competing interests exist.
  9. Cheng Huang

    Monash Proteomics and Metabolomics Facility, Monash University, Clayton, Australia
    Competing interests
    The authors declare that no competing interests exist.
  10. Christopher K Barlow

    Monash Proteomics and Metabolomics Facility, Monash University, Clayton, Australia
    Competing interests
    The authors declare that no competing interests exist.
  11. Anup D Shah

    Monash Proteomics and Metabolomics Facility, Monash University, Clayton, Australia
    Competing interests
    The authors declare that no competing interests exist.
  12. Ralf B Schittenhelm

    Monash Proteomics and Metabolomics Facility, Monash University, Clayton, Australia
    Competing interests
    The authors declare that no competing interests exist.
  13. Richelle Mychasiuk

    Department of Neuroscience, Monash University, Melbourne, Australia
    Competing interests
    The authors declare that no competing interests exist.
  14. Nigel C Jones

    Department of Neuroscience, Monash University, Melbourne, Australia
    Competing interests
    The authors declare that no competing interests exist.
  15. Sandy R Shultz

    Department of Medicine, University of Melbourne, Parkville, Australia
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-2525-8775
  16. Terence J O’Brien

    Department of Medicine, University of Melbourne, Parkville, Australia
    For correspondence
    Terence.OBrien@monash.edu
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-7198-8621

Funding

National Health and Medical Research Council (APP1087172)

  • Pablo Miguel Casillas-Espinosa

University of Melbourne (603834)

  • Pablo Miguel Casillas-Espinosa

CIHR Skin Research Training Centre (PTJ - 153051)

  • Richelle Mychasiuk

National Health and Medical Research Council (Level 2 CDF)

  • Sandy R Shultz

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Reviewing Editor

  1. Helen Scharfman, New York University Langone Medical Center, United States

Ethics

Animal experimentation: All procedures were approved by the Florey Animal Ethics Committee (ethics number 16-042-UM), adhered to the Australian code for the care and use of animals for scientific purposes and consistent with ARRIVE 2.0 guidelines

Version history

  1. Received: March 23, 2022
  2. Preprint posted: May 19, 2022 (view preprint)
  3. Accepted: March 8, 2023
  4. Accepted Manuscript published: March 9, 2023 (version 1)
  5. Version of Record published: May 24, 2023 (version 2)

Copyright

© 2023, Casillas-Espinosa et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 1,897
    views
  • 234
    downloads
  • 9
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Pablo Miguel Casillas-Espinosa
  2. Alison Anderson
  3. Anna Harutyunyan
  4. Crystal Li
  5. Jiyoon Lee
  6. Emma L Braine
  7. Rhys D Brady
  8. Mujun Sun
  9. Cheng Huang
  10. Christopher K Barlow
  11. Anup D Shah
  12. Ralf B Schittenhelm
  13. Richelle Mychasiuk
  14. Nigel C Jones
  15. Sandy R Shultz
  16. Terence J O’Brien
(2023)
Disease-modifying effects of sodium selenate in a model of drug-resistant, temporal lobe epilepsy
eLife 12:e78877.
https://doi.org/10.7554/eLife.78877

Share this article

https://doi.org/10.7554/eLife.78877

Further reading

    1. Medicine
    2. Neuroscience
    Matthew F Wipperman, Allen Z Lin ... Olivier Harari
    Tools and Resources

    Gait is impaired in musculoskeletal conditions, such as knee arthropathy. Gait analysis is used in clinical practice to inform diagnosis and to monitor disease progression or intervention response. However, clinical gait analysis relies on subjective visual observation of walking, as objective gait analysis has not been possible within clinical settings due to the expensive equipment, large-scale facilities, and highly trained staff required. Relatively low-cost wearable digital insoles may offer a solution to these challenges. In this work, we demonstrate how a digital insole measuring osteoarthritis-specific gait signatures yields similar results to the clinical gait-lab standard. To achieve this, we constructed a machine learning model, trained on force plate data collected in participants with knee arthropathy and controls. This model was highly predictive of force plate data from a validation set (area under the receiver operating characteristics curve [auROC] = 0.86; area under the precision-recall curve [auPR] = 0.90) and of a separate, independent digital insole dataset containing control and knee osteoarthritis subjects (auROC = 0.83; auPR = 0.86). After showing that digital insole derived gait characteristics are comparable to traditional gait measurements, we next showed that a single stride of raw sensor time series data could be accurately assigned to each subject, highlighting that individuals using digital insoles can be identified by their gait characteristics. This work provides a framework for a promising alternative to traditional clinical gait analysis methods, adds to the growing body of knowledge regarding wearable technology analytical pipelines, and supports clinical development of at-home gait assessments, with the potential to improve the ease, frequency, and depth of patient monitoring.

    1. Medicine
    Anika Shimonty, Fabrizio Pin ... Lynda F Bonewald
    Research Article

    Irisin, released from exercised muscle, has been shown to have beneficial effects on numerous tissues but its effects on bone are unclear. We found significant sex and genotype differences in bone from wildtype (WT) mice compared to mice lacking Fndc5 (knockout [KO]), with and without calcium deficiency. Despite their bone being indistinguishable from WT females, KO female mice were partially protected from osteocytic osteolysis and osteoclastic bone resorption when allowed to lactate or when placed on a low-calcium diet. Male KO mice have more but weaker bone compared to WT males, and when challenged with a low-calcium diet lost more bone than WT males. To begin to understand responsible molecular mechanisms, osteocyte transcriptomics was performed. Osteocytes from WT females had greater expression of genes associated with osteocytic osteolysis and osteoclastic bone resorption compared to WT males which had greater expression of genes associated with steroid and fatty acid metabolism. Few differences were observed between female KO and WT osteocytes, but with a low-calcium diet, the KO females had lower expression of genes responsible for osteocytic osteolysis and osteoclastic resorption than the WT females. Male KO osteocytes had lower expression of genes associated with steroid and fatty acid metabolism, but higher expression of genes associated with bone resorption compared to male WT. In conclusion, irisin plays a critical role in the development of the male but not the female skeleton and protects male but not female bone from calcium deficiency. We propose irisin ensures the survival of offspring by targeting the osteocyte to provide calcium in lactating females, a novel function for this myokine.